Ofatumumab plus high dose methylprednisolone followed by ofatumumab plus alemtuzumab to achieve maximal cytoreduction prior to allogeneic transplantation for 17p deleted or TP53 mutated chronic lymphocytic leukemiaFootnote^*
* Presented in part at the 2015 American Society of Hematology Annual Meeting, Orlando, FL, December 5–8, 2015

Matthew S. DavidsDepartments of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA; View further author information

Haesook T. KimBiostatistics and Computational Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA; View further author information

Lijian YuDepartments of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA; View further author information

Guadalupe De MaeyerDepartments of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA; View further author information

Mikaela McDonoughDepartments of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA; View further author information

Alexander R. VartanovDepartments of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA; View further author information

Rachael LangeyDepartments of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA; View further author information

Stacey M. FernandesDepartments of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA; View further author information

Jeffrey M. HellmanDepartments of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA; View further author information

Karen FrancoeurDepartments of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA; View further author information

Jon ArnasonDepartment of Medical Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USAView further author information

Eric D. JacobsenDepartments of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA; View further author information

Ann S. LaCasceDepartments of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA; View further author information

David C. FisherDepartments of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA; View further author information

Jennifer R. BrownDepartments of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA; Correspondence[email protected]
View further author information

show all

References

Stilgenbauer S, Zenz T. Understanding and managing ultra high-risk chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program. 2010;2010:481–488.
PubMed Web of Science ®Google Scholar
Brown JR, Kim HT, Armand P, et al. Long-term follow-up of reduced-intensity allogeneic stem cell transplantation for chronic lymphocytic leukemia: prognostic model to predict outcome. Leukemia. 2013;27:362–369.
PubMed Web of Science ®Google Scholar
Castro JE, Sandoval-Sus JD, Bole J, et al. Rituximab in combination with high-dose methylprednisolone for the treatment of fludarabine refractory high-risk chronic lymphocytic leukemia. Leukemia. 2008;22:2048–2053.
PubMed Web of Science ®Google Scholar
Lozanski G, Heerema NA, Flinn IW, et al. Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. Blood. 2004;103:3278–3281.
PubMed Web of Science ®Google Scholar
Pettitt AR, Jackson R, Carruthers S, et al. Alemtuzumab in combination with methylprednisolone is a highly effective induction regimen for patients with chronic lymphocytic leukemia and deletion of TP53: final results of the national cancer research institute CLL206 trial. J Clin Oncol. 2012;30:1647–1655.
PubMed Web of Science ®Google Scholar
Wierda WG, Kipps TJ, Mayer J, et al. Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol. 2010;28:1749–1755.
PubMed Web of Science ®Google Scholar
Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008;111:5446–5456.
PubMed Web of Science ®Google Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

References

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date